Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 21 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Lung Neoplasms 2 Carcinoma, Neuroendocrine 2 Brain Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Ras-mutated Metastatic Colorectal Cancer 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma Metastatic 1 Neoplasms 1 Kidney Neoplasms 1 Histiocytosis 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastroesophageal Adenocarcinoma 1

Interventions

Nivolumab 6 Ipilimumab 2 Gemcitabine 2 zaleplon 1 temsirolimus 1 relatlimab 1 regorafenib 1 olaparib 1 linrodostat 1 Vorinostat 1 Trastuzumab 1 Standard of Care 1 Sirolimus 1 Rehabilitation 1 Psychotherapy 1 Paclitaxel 1 Oxaliplatin 1 Niacin 1 IFL protocol 1 Health Services Needs and Demand 1 Everolimus 1 Clinical Trials, Phase IV as Topic 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × IFL protocol × 1 year × Clear all

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡